Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
AJNR Am J Neuroradiol ; 36(4): 744-50, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25542878

RESUMO

BACKGROUND AND PURPOSE: Despite major progress in treating aneurysms by coil embolization, the complete occlusion of aneurysms of >10 mm in diameter (large/giant aneurysms) remains challenging. We present a novel endovascular treatment method for large and giant cerebral aneurysms called the "maze-making and solving" technique and compare the short-term follow-up results of this technique with those of conventional coil embolization. MATERIALS AND METHODS: Eight patients (65 ± 11.5 years of age, 7 women) with large/giant unruptured nonthrombosed cerebral aneurysm (mean largest aneurysm dimension, 19 ± 4.4 mm) were treated by the maze-making and solving technique, a combination of the double-catheter technique and various assisted techniques. The coil-packing attenuation, postoperative courses, and recurrence rate of this maze group were compared with 30 previous cases (conventional group, 65.4 ± 13.0 years of age; 22 women; mean largest aneurysm dimension, 13.4 ± 3.8 mm). RESULTS: Four maze group cases were Raymond class 1; and 4 were class 2 as indicated by immediate postsurgical angiography. No perioperative deaths or major strokes occurred. Mean packing attenuation of the maze group was significantly higher than that of the conventional group (37.4 ± 5.9% versus 26.2 ± 5.6%). Follow-up angiography performed at 11.3 ± 5.4 months revealed no recurrence in the maze group compared with 39.2% in the conventional group. CONCLUSIONS: The maze-making and solving technique achieves high coil-packing attenuation for efficient embolization of large and giant cerebral aneurysms with a low risk of recurrence.


Assuntos
Embolização Terapêutica/métodos , Aneurisma Intracraniano/cirurgia , Adulto , Idoso , Angiografia Cerebral , Feminino , Humanos , Aneurisma Intracraniano/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
2.
Br J Pharmacol ; 163(6): 1237-49, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21426319

RESUMO

BACKGROUND AND PURPOSE: Cerebral aneurysm is a frequent cerebrovascular event and a major cause of fatal subarachnoid haemorrhage, but there is no medical treatment for this condition. Haemodynamic stress and, recently, chronic inflammation have been proposed as major causes of cerebral aneurysm. Nevertheless, links between haemodynamic stress and chronic inflammation remain ill-defined, and to clarify such links, we evaluated the effects of prostaglandin E(2) (PGE(2) ), a mediator of inflammation, on the formation of cerebral aneurysms. EXPERIMENTAL APPROACH: Expression of COX and prostaglandin E synthase (PGES) and PGE receptors were examined in human and rodent cerebral aneurysm. The incidence, size and inflammation of cerebral aneurysms were evaluated in rats treated with COX-2 inhibitors and mice lacking each prostaglandin receptor. Effects of shear stress and PGE receptor signalling on expression of pro-inflammatory molecules were studied in primary cultures of human endothelial cells (ECs). KEY RESULTS: COX-2, microsomal PGES-1 and prostaglandin E receptor 2 (EP(2) ) were induced in ECs in the walls of cerebral aneurysms. Shear stress applied to primary ECs induced COX-2 and EP(2) . Inhibition or loss of COX-2 or EP(2) in vivo attenuated each other's expression, suppressed nuclear factor κB (NF-κB)-mediated chronic inflammation and reduced incidence of cerebral aneurysm. EP(2) stimulation in primary ECs induced NF-κB activation and expression of the chemokine (C-C motif) ligand 2, essential for cerebral aneurysm. CONCLUSIONS AND IMPLICATIONS: These results suggest that shear stress activated PGE(2) -EP(2) pathway in ECs and amplified chronic inflammation via NF-κB. We propose EP(2) as a therapeutic target in cerebral aneurysm.


Assuntos
Dinoprostona/metabolismo , Aneurisma Intracraniano/metabolismo , NF-kappa B/metabolismo , Receptores de Prostaglandina E Subtipo EP2/metabolismo , Animais , Quimiocina CCL2/genética , Quimiocina CCL2/metabolismo , Inibidores de Ciclo-Oxigenase 2/farmacologia , Dinoprostona/genética , Humanos , Inflamação/genética , Inflamação/metabolismo , Aneurisma Intracraniano/tratamento farmacológico , Camundongos , Camundongos Knockout , NF-kappa B/genética , Prostaglandina-Endoperóxido Sintases/genética , Prostaglandina-Endoperóxido Sintases/metabolismo , Ratos , Receptores de Prostaglandina E Subtipo EP2/genética , Transdução de Sinais
3.
Gene Ther ; 17(9): 1117-23, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20428211

RESUMO

Cerebral aneurysm (CA) rupture is one of the leading causes of stroke death. Recent experimental studies suggest that the pathophysiology of CA is closely associated with inflammation. A transcription factor, Ets-1, has been shown to regulate vascular inflammation and remodeling in a physiological and pathological condition. The expression and role of Ets-1 in CA development has been investigated in this study. Ets-1 was expressed and activated mainly in vascular smooth muscle cells (VSMCs) in both experimentally induced rat CAs and human CA walls by immunohistochemistry, western blotting and enzyme-linked mobility shift assay. The downstream target of Ets-1 in CA development was identified by chromatin immunoprecipitation (CHIP) analysis. CHIP analysis revealed that Ets-1 transactivated monocyte chemoattractant protein-1 (MCP-1) expression in CA walls. Treatment with ets decoy oligodeoxynucleotides resulted in the prevention of CA enlargement, upregulation of MCP-1 expression and increase in macrophage accumulation in CA walls. In conclusion, Ets-1 mediates MCP-1 expression in VSMCs in CA walls, thus promoting the progression of CAs. Inhibition of DNA-binding activity of Ets-1 may lead to the prevention of human CA enlargement and rupture. Results of this study will provide us a clue to a novel therapeutic strategy for CAs.


Assuntos
Quimiocina CCL2/genética , Aneurisma Intracraniano/etiologia , Músculo Liso Vascular/metabolismo , Miócitos de Músculo Liso/metabolismo , Proteína Proto-Oncogênica c-ets-1/metabolismo , Animais , Quimiocina CCL2/metabolismo , Imunoprecipitação da Cromatina , Humanos , Imuno-Histoquímica , Aneurisma Intracraniano/metabolismo , Aneurisma Intracraniano/patologia , Masculino , Músculo Liso Vascular/citologia , Miócitos de Músculo Liso/citologia , Ratos , Ratos Sprague-Dawley
4.
Dev Biol ; 244(1): 37-43, 2002 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-11900457

RESUMO

The hermaphroditic freshwater clam Corbicula leana reproduces by androgenesis. In the control (androgenetic development), all maternal chromosomes and maternal centrosomes at the meiotic poles were extruded as the two first polar bodies, and subsequently, second meiosis did not occur. But, in C. leana eggs treated with cytochalasin D (CD) to inhibit polar body extrusion, the second meiosis occurred. At metaphase-I, the spindle showed the typical bipolar structure and two spheroid centrosomes were located at its poles. All the maternal chromosomes were divided at anaphase-I, but they were not extruded as polar bodies due to the effects of CD. After completion of first meiosis, the maternal centrosomes split into four. At the second meiosis, twin or tetrapolar spindles were formed and two groups of maternal chromosomes divided into four sets of chromosomes. After the second meiosis, the spindle disassociated and the four maternal centrosomes disappeared. Four groups of maternal chromosomes transformed into the four female pronuclei. Male and female pronuclei became metaphase chromosomes of the first mitosis. The present study clearly indicates that typical meiosis systems still proceed in androgenetic triploid C. leana. We conclude that the androgenetic form may have arisen from the meiotic form.


Assuntos
Centrossomo/fisiologia , Mapeamento Cromossômico , Citocalasina D/farmacologia , Meiose/efeitos dos fármacos , Moluscos/embriologia , Moluscos/genética , Óvulo/fisiologia , Animais , Ciclo Celular/efeitos dos fármacos , Polaridade Celular/efeitos dos fármacos , Feminino , Fertilização , Masculino , Óvulo/citologia , Óvulo/efeitos dos fármacos
6.
Oncol Rep ; 8(4): 835-9, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11410794

RESUMO

This retrospective analysis evaluates the treatment results and prognostic factors of 114 patients with ductal carcinoma in situ (DCIS) undergoing breast conserving therapy (BCT) at Keio University Hospital Department of Radiology, between 1988 and 1997. A total of 132 patients with DCIS of the breast came to our hospital between 1988 and 1997, and 114 cases were suitable candidates for BCT. All of the patients were female and ranged in age from 26 to 81 years (median 46). Ninety-one patients were premenopausal, and 23 were postmenopausal. Median clinical tumor size was 2.0 cm (0-8.0 cm). Postoperatively 48 cases received 50 Gy/25 fractions of external irradiation to the whole breast via tangential ports. The follow-up period after treatment ranged from 11 to 162 months (median 46.7). The local relapse-free rate and overall survival rate of the 114 patients were 89.5% and 100%, respectively. Local failure and regional nodal failure occurred in 12 and 1 patient, respectively. Radiotherapy was a significant risk factor for local failure (p=0.05). No postmenopausal patients developed local failure, but the difference did not reach statistical significance (p=0.103). The 12 recurrent cases underwent additional surgery and all remain alive without recurrence, to date, i.e., at least 16 months. Breast-conserving surgery plus irradiation is appropriate treatment for DCIS patients.


Assuntos
Neoplasias da Mama/terapia , Carcinoma Intraductal não Infiltrante/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias da Mama/patologia , Carcinoma Intraductal não Infiltrante/patologia , Terapia Combinada , Intervalo Livre de Doença , Feminino , Seguimentos , Humanos , Mastectomia Segmentar , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/prevenção & controle , Recidiva Local de Neoplasia/cirurgia , Estadiamento de Neoplasias , Pós-Menopausa , Pré-Menopausa , Prognóstico , Modelos de Riscos Proporcionais , Dosagem Radioterapêutica , Estudos Retrospectivos , Resultado do Tratamento
7.
J Hypertens ; 19(6): 1095-103, 2001 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11403359

RESUMO

OBJECTIVE: Prostaglandin (PG) E2, a major arachidonic acid metabolite in the kidney, acts on four receptor subtypes (EP1, EP2, EP3 and EP4). One of major causes of end-stage renal failure is hypertensive renal disease, in which enhanced renal PGE2 production has been shown. In this study, to explore the pathophysiological significance of EP subtypes in the kidney, we examined the role of EP subtypes on proliferation of mesangial cells (MCs) from stroke-prone spontaneously hypertensive rats (SHRSPs), which show faster growth than those from normotensive Wistar-Kyoto rats (WKYs). DESIGN AND METHODS: Using MCs from SHRSPs and WKYs, we investigated DNA synthesis and its upstream event, the phosphorylation of extracellular signal-regulated kinase (ERK), together with the gene expression of EP subtypes. RESULTS: Sulprostone, an EP1 agonist, dose-dependently increased DNA synthesis and the phosphorylation of ERK in MCs from both strains. The EP4 agonist, 11-deoxy-PGE1, inhibited sulprostone-induced phosphorylation of ERK in WKY-MCs. In contrast, 11-deoxy-PGE1 failed to inhibit the ERK activity in SHRSP-MCs. Interestingly, cAMP production mediated by EP4 was markedly attenuated in SHRSP-MCs as compared with that in WKY-MCs, despite the overproduction of endogenous PGE2 in SHRSP-MCs. Similar gene expressions of EP1 and EP4 and only faint expression of EP3 were detected in MCs from both strains. CONCLUSIONS: These results indicate that the PGE2/EP4 system counteracts the PGE2/EP1 system at the level of the intracellular signaling pathway. The altered EP4 signaling may play a critical role in the exaggerated mesangial growth in SHRSPs.


Assuntos
Dinoprostona/análogos & derivados , Dinoprostona/fisiologia , Mesângio Glomerular/fisiopatologia , Receptores de Prostaglandina E/fisiologia , Animais , Células Cultivadas , AMP Cíclico/biossíntese , DNA/biossíntese , Dinoprostona/farmacologia , Expressão Gênica , Mesângio Glomerular/efeitos dos fármacos , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Fosforilação , Ratos , Ratos Endogâmicos SHR , Ratos Endogâmicos WKY , Receptor Cross-Talk , Receptores de Prostaglandina E/agonistas , Receptores de Prostaglandina E/antagonistas & inibidores , Receptores de Prostaglandina E/classificação , Receptores de Prostaglandina E/genética , Receptores de Prostaglandina E Subtipo EP1 , Receptores de Prostaglandina E Subtipo EP4 , Transdução de Sinais
8.
J Hypertens ; 19(3): 475-83, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11288818

RESUMO

OBJECTIVE: Brain natriuretic peptide (BNP) is a ventricular hormone with natriuretic, diuretic and vasodilatory actions. Acute infusion of BNP reduces cardiac pre- and after-load in healthy and diseased subjects, but its long-term therapeutic usefulness remains unclear. DESIGN: We prepared a monoclonal antibody specific to mouse BNP, and characterized transgenic mice overexpressing BNP in the liver (BNP-Tg mice) as a model of its chronic overproduction. METHODS: Radioimmunoassay and neutralization experiments using the monoclonal antibody, KY-mBNP-I, were performed in BNP-Tg mice in conjunction with examinations of blood pressure (BP) and other markers for body fluid homeostasis. RESULTS: We developed highly sensitive radioimmunoassay to mouse BNP. In BNP-Tg mice, the plasma BNP concentration increased more than 100-fold, while ventricular BNP concentration did not alter, suggesting that ventricular BNP production was not down-regulated in BNP-Tg mice. The BNP concentration in the kidneys was 10-fold higher than nontransgenic (nonTg) littermates, accompanied with marked reduction in the atrial natriuretic peptide (ANP) concentration, that may be due to binding of circulating BNP to the natriuretic peptide receptors. BNP-Tg mice showed significantly low arterial BP, and a bolus intraperitoneal administration of KYmBNP-I completely abolished enhanced cGMP excretion in the urine and significantly increased the systolic BP. CONCLUSION: These results suggested that biological actions of BNP last and reduce cardiac overload in its longterm overproduction in the transgenic mouse model.


Assuntos
Anticorpos Monoclonais/farmacologia , Peptídeo Natriurético Encefálico/antagonistas & inibidores , Peptídeo Natriurético Encefálico/fisiologia , Animais , Fator Natriurético Atrial/fisiologia , Pressão Sanguínea , Coração/anatomia & histologia , Rim/fisiologia , Fígado/fisiologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Transgênicos , Peptídeo Natriurético Encefálico/genética , Testes de Neutralização , Tamanho do Órgão , Radioimunoensaio , Renina/sangue
9.
Anticancer Res ; 21(1A): 325-8, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11299757

RESUMO

BACKGROUND: To improve the radiotherapy results, we evaluated etoposide as an effective radiosensitizer by using cultured cell-lines. MATERIALS AND METHODS: Four cell lines having different doubling times (DT) were used: V79 (Chinese hamster fibroblasts, DT = 9 hours), (1), T24 (human bladder cancer, DT = 19 hours) (2), MDA-MB231 (human breast cancer, DT = 25-30 hours) (3) and RMG1 (human ovarian cancer, DT = 50 hours) (4). Cell survival was determined by colony assay and cell cycle analysis was performed by flow-cytometry. RESULTS: The survival curves showed RMG1 to be the most radiosensitive, followed by MDA-MB231, T24, and V79. V79 was most chemosensitive to etoposide, followed by T24, MDA-MB231 and RMG1. Neither 24-hours exposure to etoposide (< or = 0.05 microgram/ml) or 0.5-h exposure (< or = 1.0 microgram/ml) had any cell killing effect on any of the cell lines used. When the cells were irradiated after exposure to 1 microgram/ml of etoposide for 0.5 hours, no radiosensitization was observed in any of the cell lines except V79. Enhanced radiosensitivity was observed in V79 and T24 cells (which have a relatively short DT) when they were incubated with 0.05 microgram/ml etoposide for 24 hours but no enhanced effect was seen in MDA-MB231 or RMG1 cells (which have a relatively long DT). CONCLUSION: It is suggested that a combination of radiation and etoposide may be useful in the treatment of rapidly growing cancer.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Etoposídeo/farmacologia , Neoplasias/tratamento farmacológico , Neoplasias/radioterapia , Radiossensibilizantes/farmacologia , Animais , Antineoplásicos Fitogênicos/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/radioterapia , Ciclo Celular/efeitos dos fármacos , Ciclo Celular/efeitos da radiação , Sobrevivência Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos da radiação , Terapia Combinada , Cricetinae , Relação Dose-Resposta a Droga , Relação Dose-Resposta à Radiação , Etoposídeo/administração & dosagem , Feminino , Humanos , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/radioterapia , Radiossensibilizantes/administração & dosagem , Células Tumorais Cultivadas , Ensaio Tumoral de Célula-Tronco , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/radioterapia
10.
Int J Mol Med ; 7(5): 509-13, 2001 May.
Artigo em Inglês | MEDLINE | ID: mdl-11295113

RESUMO

Carbon beam radiotherapy for cancer patients was initiated in Japan in June 1994. This study attempts to clarify the radiobiological effects of heavy ion beams. In this study, human cancer cell lines (RMG-1, MDA-MB231) and V79 cells were used. The cell killing was determined by colony forming assay, and mutation induction was determined by counting the number of 6-thioguanine resistant colonies (hprt locus mutation assay). The cell lines were irradiated with carbon (20 or 80 keV/microm) or neon beams (80 keV/microm). Carbon ions with a higher LET value (80 keV/microm) had an enhanced cytotoxic effect compared to those with a lower LET value (20 keV/microm). Carbon beams produced a slightly stronger cytotoxic effect than neon beams when irradiated at the same LET level (80 keV/microm), but the difference was not remarkable. The mutant fraction was significantly higher in all cell lines when they were irradiated with heavy ion beams, compared to the results for X-ray irradiation. The mutant fraction increased when the LET of the carbon beams increased. At equivalent LET values, the mutant fraction was lower for neon beams than for carbon beams. Fractionation of carbon beam irradiation had no effect on survival, but reduced the mutant fraction. Neon beams might be more appropriate for heavy ion therapy, especially when higher doses are being used. In addition, the fractionation of heavy ion beam administration might be appropriate for reducing the mutant fraction.


Assuntos
Sobrevivência Celular/efeitos da radiação , Íons Pesados , Mutação/efeitos da radiação , Animais , Carbono , Linhagem Celular , Relação Dose-Resposta à Radiação , Humanos , Neônio , Células Tumorais Cultivadas , Raios X
12.
Biomed Pharmacother ; 54 Suppl 1: 183s-186s, 2000 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10915020

RESUMO

Laparoscopic adrenalectomy has been rapidly accepted for treatment of benign adrenal tumors. To evaluate the advantages of laparoscopic adrenalectomy, we examined 55 patients who underwent laparoscopic adrenalectomy. In all patients, adrenal tumors were successfully removed. The mean operating time was 143 minutes, and the estimated mean blood loss was 49 mL in all patients. The postoperative course was uneventful in all cases. The mean frequency of administration of analgesics was only 2.9 times, and the time elapsed to first walking after surgery was 17 hours. The peak white blood cell count and C-reactive protein values after surgery were 8,266 +/- 1,963/mm3 and 2.5 +/- 1.2 mg/dL, respectively. Of the 55 patients, 44 underwent total adrenalectomy and another 11 underwent partial adrenalectomy, which was introduced in the expectation of preserving normal adrenal cortex; it is therefore indicated in solitary and peripherally located benign tumors. The mean operating time was 154 minutes for the total adrenalectomy, which was longer than that of partial adrenalectomy (92 minutes). The estimated blood loss was 50 mL for the total and 46 mL for the partial adrenalectomy. The postoperative course was uneventful and surgical outcome was excellent in each group. In conclusion, our results are encouraging enough to suggest that laparoscopic adrenalectomy should be a preferential therapeutic option for benign adrenal tumors; also, partial adrenalectomy could be a safe, effective, and less invasive procedure in selected cases.


Assuntos
Neoplasias das Glândulas Suprarrenais/cirurgia , Adrenalectomia , Laparoscopia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos , Estudos Retrospectivos
13.
Protein Eng ; 13(3): 193-6, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10775660

RESUMO

In order to examine how a protein can be effectively stabilized, two intramolecular cross-links, Glu35-Trp108 and Lys1-His15, which have few unfavorable interactions in the folded state, were simultaneously introduced into hen lysozyme. Both of the intramolecularly cross-linked lysozymes, 35-108 CL and 1-15 CL, containing cross-links Glu35-Trp108 and Lys1-His15, respectively, showed increases in thermal stability of 13.9 and 5.2 degrees C, respectively, over that of wild type, at pH 2.7. On the other hand, a doubly cross-linked lysozyme showed an increase in thermal stability of 20.8 degrees C over that of wild type, under identical conditions. Since the sum of the differences in denaturation temperature between wild type and each of the cross-linked lysozymes was nearly equal to that between wild type and the doubly cross-linked lysozyme, we suggest that the efficient stabilization of the lysozyme molecule was the direct result of the double intramolecular cross-links.


Assuntos
Muramidase/química , Dobramento de Proteína , Substituição de Aminoácidos , Animais , Sítios de Ligação , Varredura Diferencial de Calorimetria , Galinhas , Clara de Ovo , Estabilidade Enzimática , Ácido Glutâmico , Histidina , Temperatura Alta , Lisina , Mutagênese Sítio-Dirigida , Proteínas Recombinantes/química , Termodinâmica , Triptofano
14.
Int J Radiat Oncol Biol Phys ; 46(4): 815-22, 2000 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-10705001

RESUMO

PURPOSE: The two-portal tangential irradiation technique has usually been applied to breast cancer patients after breast-conserving surgery (1, 2) and is expected to irradiate the axillary lymph node region to some extent (3). We investigated the range of the axillary region covered by this technique and tried to devise an optimal irradiation technique (modified tangential irradiation) that would cover the axillary lymph node region properly. METHODS AND MATERIALS: We checked the status of the surgical clips left at axillary lymph node sites by reviewing the simulator films and planning CT scans of 63 patients who underwent axillary dissection of level I, I-II, or I-III lymph nodes. Then we created the modified tangential irradiation technique and applied this technique to 16 patients and checked the irradiation volume by CT scans. RESULTS: We found that all of the surgical clips on lateral-view simulator films were on the ventral side of the dorsal edge line of the humeral head. All but one clip were on the caudal side of the caudal edge line of the humeral head. Accordingly, it is possible to irradiate almost all axillary lymph node regions by setting the dorsal edge of the irradiation field on lateral-view simulator films at the dorsal edge of the humeral head and the cranial edge at the caudal edge of the humeral head. CONCLUSIONS: All breast tissue and the entire axillary lymph node region can be covered by the modified tangential irradiation technique without increasing the lung volume irradiated.


Assuntos
Neoplasias da Mama/radioterapia , Irradiação Linfática/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Axila , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Terapia Combinada , Feminino , Humanos , Metástase Linfática/radioterapia , Mastectomia Segmentar , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Radioterapia/métodos , Instrumentos Cirúrgicos
16.
Kidney Int ; 56(2): 589-600, 1999 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10432398

RESUMO

BACKGROUND: High glucose reportedly stimulates prostaglandin (PG) E2 production and DNA synthesis in mesangial cells (MCs). However, the pathophysiological significance of PGE2 in MCs has remained unclear. METHODS: The effects of prostanoids on [3H]-thymidine uptake and cAMP production in rat MCs cultured with 5.6 mM glucose, 25 mM glucose, or 5.6 mM glucose supplemented with 19.4 mM mannitol were examined. The gene expression of PGE2 receptor (EP) subtypes in MCs was analyzed with Northern blotting techniques. RESULTS: Northern blotting indicated EP1 and EP4 gene expression in MCs. EP1 agonists and PGE2 stimulated [3H]-thymidine uptake in MCs. EP1 antagonists dose dependently attenuated high-glucose-induced [3H]-thymidine uptake, which suggests EP1 involvement, by an increase in intracellular Ca2+, in DNA synthesis of MCs. On the other hand, forskolin, db-cAMP, and 11-deoxy-PGE1, an EP4/EP3/EP2 agonist, significantly decreased DNA synthesis in MCs. These inhibitory effects are thought to be mediated via EP4 as a result of an increase in cAMP synthesis. The effects via EP4 seem to be particularly important because PGE2-induced cAMP synthesis was significantly attenuated in the high-glucose group compared with the mannitol group, in which [3H]-thymidine uptake did not increase in spite of augmented PGE2 production. CONCLUSION: The increase in DNA synthesis in MCs under high-glucose conditions can be explained, at least in part, by the high-glucose-induced inhibition of cAMP production via EP4, which augments EP1 function in conjunction with the overproduction of PGE2.


Assuntos
Mesângio Glomerular/fisiologia , Glucose/farmacologia , Receptores de Prostaglandina E/genética , Receptores de Prostaglandina E/metabolismo , 1-Metil-3-Isobutilxantina/farmacologia , Alprostadil/análogos & derivados , Alprostadil/farmacologia , Animais , Antiulcerosos/farmacologia , Northern Blotting , Cálcio/metabolismo , Células Cultivadas , Colforsina/farmacologia , AMP Cíclico/metabolismo , Dinoprostona/análogos & derivados , Dinoprostona/farmacologia , Expressão Gênica/efeitos dos fármacos , Mesângio Glomerular/química , Mesângio Glomerular/citologia , Masculino , Indutores da Menstruação/farmacologia , Inibidores de Fosfodiesterase/farmacologia , Prostaglandinas E Sintéticas/farmacologia , RNA Mensageiro/análise , Ratos , Ratos Endogâmicos WKY , Receptores de Prostaglandina E/antagonistas & inibidores , Receptores de Prostaglandina E Subtipo EP1 , Timidina/farmacocinética , Trítio
17.
J Gastroenterol ; 34(3): 378-82, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10433016

RESUMO

We report a case of primary small cell carcinoma of the esophagus in a patient with achalasia in whom pro-gastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) levels were measured. Although chemotherapy markedly reduced the size of the primary tumor and lymph node metastases, it had no effect on liver metastases. The tumor marker levels decreased after chemotherapy as the primary tumor and lymph node metastases decreased in size, and they increased as the liver metastases enlarged. However, there was a discrepancy between the levels of ProGRP and NSE during the patient's clinical course. We demonstrate the usefulness of measuring ProGRP and NSE levels to assess the effect of chemotherapy in patients with esophageal small cell carcinoma.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biomarcadores Tumorais/análise , Carcinoma de Células Pequenas/diagnóstico , Neoplasias Esofágicas/diagnóstico , Fragmentos de Peptídeos/análise , Peptídeos/análise , Fosfopiruvato Hidratase/análise , Carcinoma de Células Pequenas/complicações , Carcinoma de Células Pequenas/tratamento farmacológico , Cisplatino/administração & dosagem , Ciclofosfamida/administração & dosagem , Acalasia Esofágica/complicações , Acalasia Esofágica/diagnóstico por imagem , Acalasia Esofágica/terapia , Neoplasias Esofágicas/complicações , Neoplasias Esofágicas/tratamento farmacológico , Esofagoscopia , Etoposídeo/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/metabolismo , Peptídeos/metabolismo , Fosfopiruvato Hidratase/metabolismo , Prognóstico , Proteínas Recombinantes/análise , Proteínas Recombinantes/metabolismo , Sensibilidade e Especificidade , Tomografia Computadorizada por Raios X , Resultado do Tratamento
18.
Int Surg ; 84(2): 151-4, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10408287

RESUMO

A rare case of an epithelial splenic cyst showing a high production of the carbohydrate antigen 19-9 (CA19-9) is presented. A 19-year-old female with high fever and loss of appetite was diagnosed as having a splenic cyst. Laboratory data revealed unusually elevated serum levels of both CA19-9 and CA125. The histological diagnosis was an epithelial splenic cyst, and immunohistochemically the wall of the splenic cyst was strongly positive for CA19-9 and slightly positive for both CA125 and CEA. Fluid in the splenic cyst contained quite high levels of CA19-9, CA125 and CEA. After splenectomy, the serum levels of CA19-9 and CA125 gradually decreased. These findings suggested that the splenic cyst produced CA19-9, CA125 and CEA. And with very high levels of CA19-9 and CA1 25 in the cyst, some had entered into systemic circulation.


Assuntos
Antígeno CA-19-9/biossíntese , Cistos/metabolismo , Esplenopatias/metabolismo , Adulto , Antígeno Ca-125/metabolismo , Cistos/imunologia , Cistos/patologia , Cistos/cirurgia , Feminino , Humanos , Imuno-Histoquímica , Período Pós-Operatório , Esplenectomia , Esplenopatias/imunologia , Esplenopatias/patologia , Esplenopatias/cirurgia
19.
Kidney Int ; 53(4): 979-85, 1998 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9551407

RESUMO

Adrenomedullin (AM), a potent vasorelaxant and natriuretic peptide isolated from human pheochromocytoma, is present in the kidney and secreted from endothelial cells (EC) and vascular smooth muscle cells (VSMC), but the functional role of AM is still unclear. To clarify the significance of AM as a local regulator, we investigated its secretion and action in cultured cells, and examined the effects of neutralization using a specific monoclonal antibody against AM. The prepared antibody directed against the ring structure showed a high affinity for human and rat AM. Using radioimmunoassay with this antibody, we found significant secretion from cultured rat mesangial cells (MC) of a 6-kDa mature form of AM as seen from EC and VSMC. The addition of AM into cultured cells dose-dependently increased cAMP production and potently inhibited PDGF-stimulated thymidine incorporation. Pretreatment with the monoclonal antibody completely abolished cAMP increase induced by exogenous AM. Moreover, antibody neutralization of endogenously secreted AM in cultured EC, but not in MC or VSMC, markedly (by approximately 70%) reduced basal cAMP production and significantly (1.7-fold) enhanced DNA synthesis. These results indicate that AM, acting as an autocrine/paracrine regulator, exerts an antiproliferative action on EC and MC, and suggest its role as a local modulator of endothelial and mesangial function.


Assuntos
Comunicação Autócrina/fisiologia , Mesângio Glomerular/citologia , Comunicação Parácrina/fisiologia , Peptídeos/metabolismo , Vasodilatadores/metabolismo , Adrenomedulina , Animais , Anticorpos Monoclonais , Aorta/citologia , Bovinos , Divisão Celular/efeitos dos fármacos , Células Cultivadas , AMP Cíclico/metabolismo , Endotélio/citologia , Humanos , Músculo Liso Vascular/citologia , Testes de Neutralização , Fragmentos de Peptídeos/metabolismo , Peptídeos/imunologia , Radioimunoensaio , Ratos , Vasodilatadores/imunologia
20.
Hypertension ; 30(3 Pt 1): 358-62, 1997 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-9314417

RESUMO

Angiotensin II acts on at least two receptor subtypes, AT1 and AT2. Although the physiological role of the AT2 receptor is still poorly defined, it may be implicated in inhibition of cell growth, vasorelaxation, and apoptosis. In the present study, to investigate the role of the AT2 receptor in the kidney and its implication in hypertensive states, we examined its expression using cultured mesangial cells (MC) from normotensive Wistar-Kyoto rats (WKY) and from stroke-prone spontaneously hypertensive rats (SHRSP). Receptor binding assays were performed using a nonselective ligand, [Sar1,Ile8]angiotensin II, or AT2-selective CGP42112A. Binding assays revealed that MC from WKY exhibited both AT1 and AT2 receptors, the ratio of which was confluence-dependent. In contrast, MC from SHRSP, whose proliferation activity was much higher than those from WKY, showed only the AT1 subtype. In receptor binding and Northern blot analyses, expression of the AT2 receptor of WKY-MC was low in the growing state but significantly induced upon confluence to become abundant in the post-confluent state, whereas that of SHRSP-MC was undetectable in either state. Gene expressions of AT1A and AT1B receptors were not significantly altered in either strain during the time in culture. These results indicate that the mesangial AT2-receptor expression is growth-dependent and suggest a role in the inhibition of MC growth in WKY. Much lower expression of the AT2 receptor in MC from SHRSP may suggest involvement in their higher proliferation activity and possibly in consequent renal disorders.


Assuntos
Mesângio Glomerular/citologia , Mesângio Glomerular/metabolismo , Receptores de Angiotensina/metabolismo , Animais , Divisão Celular/fisiologia , Células Cultivadas , Transtornos Cerebrovasculares/genética , Expressão Gênica , Predisposição Genética para Doença , Masculino , Ratos , Ratos Endogâmicos SHR/genética , Ratos Endogâmicos WKY , Receptores de Angiotensina/classificação , Receptores de Angiotensina/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA